Biological and clinical significance of her2 overexpression in Breast Cancer
- 1 January 2001
- journal article
- review article
- Published by Springer Nature in Breast Cancer
- Vol. 8 (1) , 45-51
- https://doi.org/10.1007/bf02967477
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancerOncogene, 2000
- ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalingThe EMBO Journal, 1997
- Activation of p70/p85 S6 kinase by a pathway independent of p21fi rasNature, 1994
- Analysis of cerbB2 expression using a panel of 6 commercially available antibodiesPathology, 1994
- Betacellulin: a mitogen from pancreatic beta cell tumorsScience, 1993
- A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transductionCell, 1992
- Isolation of the NeuHER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cellsCell, 1992
- Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulationBiochemistry, 1990
- Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptorNature, 1986
- Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cellsNature, 1984